Results 91 to 100 of about 1,268 (176)

Efgartigimod as Rescue Medication in a Patient with Therapy-Refractory Myasthenic Crisis [PDF]

Myasthenic crises (MC) are potentially life-threatening acute exacerbations of myasthenia gravis (MG) characterized by profound muscle weakness, bulbar symptoms, and potential for respiratory failure.
Mück, Anna, Diel, Norma J., Krämer-Best, Heidrun H., Gerner, Stefan T., Alhaj Omar, Omar, Huttner, Hagen B.   +5 more
core   +2 more sources

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Preliminary Observations on the Efficacy of Efgartigimod Therapy in Autoimmune Nodopathy

European Journal of Neurology
ABSTRACTBackgroundAutoimmune nodopathy exhibits suboptimal responses to conventional immunotherapies. This study investigates the efficacy and safety of efgartigimod, a neonatal Fc receptor blocker, in this condition.MethodsA prospective single‐center study enrolled four antibody‐confirmed autoimmune nodopathy patients receiving weekly efgartigimod (10 
Hongfei Tai, Songtao Niu, Hua Pan, Fan Jian, Zhenxian Hu, Na Chen, Ying Wang, Zaiqiang Zhang   +7 more
openaire   +2 more sources

Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis

Neurology and Therapy
Myasthenic crisis (MC) is a potentially fatal complication of myasthenia gravis (MG), often requiring intensive care and rescue therapies such as intravenous immunoglobulin (IVIG) and corticosteroids.
Nicasio Rini, Flora D’Amico, Valentina Portera, Filippo Brighina, Vincenzo Di Stefano   +4 more
doaj   +1 more source

Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis

Clinical and Translational Medicine
Background Myasthenia gravis (MG) is an autoimmune disease predominantly driven by autoantibodies targeting acetylcholine receptor (AChR), resulting in muscle weakness.
Hui‐Ning Li, Jingjing Liu, Xiao‐Yu Huang, Lijie Zhu, Zhirui Liu, Chun‐Sheng Yang, Bo Zhang, Shixiong Huang, Fu‐Dong Shi, Zhigang Cai, Chao Zhang   +10 more
doaj   +1 more source

Case Report: A Patient with Lambert-Eaton Myasthenic Syndrome Successfully Treated with Efgartigimod

International Medical Case Reports Journal
Lizhu Han,1,2 Jili Shen,3 Jie Wei,3 Yue Zhang2 1Department of Neurology, Anhui No.2 Provincial People’s Hospital, Hefei, Anhui, People’s Republic of China; 2Department of Neurology, National Center for Neurological Disorders, Huashan Rare Disease Centre,
Han L, Shen J, Wei J, Zhang Y
doaj  

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT). [PDF]

J Neurol
Howard JF, Saccà F, Hoffmann S, Attarian S, De Bleecker JL, Beauchamp J, Brauer E, Kerstens R, Vissing J, Meisel A, ADAPT Study Group.   +10 more
europepmc   +1 more source

Correction to: Efgartigimod: First Approval

Drugs, 2022
openaire   +1 more source

Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect. [PDF]

Front Immunol
Aili K, Lu M, Zhao N, Maimaiti M.
europepmc   +1 more source

Successful treatment of anti-LGI1-associated autoimmune encephalitis with efgartigimod: A case report and literature review. [PDF]

Medicine (Baltimore)
Gao R, Hong Y, Zhou G.
europepmc   +1 more source